Literature DB >> 17534570

Pulmonary hypertension: current diagnosis and treatment.

Stephan Rosenkranz1.   

Abstract

Pulmonary hypertension (PH) is a devastating disease that - if untreated - is characterized by a poor prognosis. According to the current classification (Venice, 2003), pulmonary arterial hypertension (PAH) is distinguished from other forms of PH. Recent advances in drug therapy have led to a dramatic improvement of medical care particularly in patients with PAH. Hence, early establishment of the diagnosis appears increasingly important. This review article gives an overview on the definition, classification, pathophysiology, and clinical presentation of various forms of PH. Furthermore, it summarizes the recommended diagnostic work-up and the current treatment options particularly in PAH, with special emphasis on prostanoids, endothelin receptor antagonists (ERAs), and phosphopdiesterase type 5 (PDE5) inhibitors such as sildenafil. Finally, novel developments are being discussed which currently represent an exciting field of research.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17534570     DOI: 10.1007/s00392-007-0526-8

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  77 in total

1.  Hemodynamic monitoring during sexual intercourse and physical exercise in a patient with chronic heart failure and pulmonary hypertension.

Authors:  Bodo Cremers; Barbro Kjellström; Michael Südkamp; Michael Böhm
Journal:  Am J Med       Date:  2002-04-01       Impact factor: 4.965

2.  The registry of the international society for heart and lung transplantation: nineteenth official report-2002.

Authors:  Marshall I Hertz; David O Taylor; Elbert P Trulock; Mark M Boucek; Paul J Mohacsi; Leah B Edwards; Berkeley M Keck
Journal:  J Heart Lung Transplant       Date:  2002-09       Impact factor: 10.247

3.  Sildenafil citrate therapy for pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

4.  Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension.

Authors:  Anna Fijalkowska; Marcin Kurzyna; Adam Torbicki; Grzegorz Szewczyk; Michal Florczyk; Piotr Pruszczyk; Monika Szturmowicz
Journal:  Chest       Date:  2006-05       Impact factor: 9.410

5.  Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension.

Authors:  T C Yeo; K S Dujardin; C Tei; D W Mahoney; M D McGoon; J B Seward
Journal:  Am J Cardiol       Date:  1998-05-01       Impact factor: 2.778

6.  Tricuspid annular displacement predicts survival in pulmonary hypertension.

Authors:  Paul R Forfia; Micah R Fisher; Stephen C Mathai; Traci Housten-Harris; Anna R Hemnes; Barry A Borlaug; Elzbieta Chamera; Mary C Corretti; Hunter C Champion; Theodore P Abraham; Reda E Girgis; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2006-08-03       Impact factor: 21.405

7.  Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients.

Authors:  P J Currie; J B Seward; K L Chan; D A Fyfe; D J Hagler; D D Mair; G S Reeder; R A Nishimura; A J Tajik
Journal:  J Am Coll Cardiol       Date:  1985-10       Impact factor: 24.094

8.  Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension.

Authors:  Ronald J Raymond; Alan L Hinderliter; Park W Willis; David Ralph; Edgar J Caldwell; William Williams; Neil A Ettinger; Nicholas S Hill; Warren R Summer; Bennett de Boisblanc; Todd Schwartz; Gary Koch; Linda M Clayton; Maria M Jöbsis; James W Crow; Walker Long
Journal:  J Am Coll Cardiol       Date:  2002-04-03       Impact factor: 24.094

9.  Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide.

Authors:  Evangelos Michelakis; Wayne Tymchak; Dale Lien; Linda Webster; Kyoko Hashimoto; Stephen Archer
Journal:  Circulation       Date:  2002-05-21       Impact factor: 29.690

10.  Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment.

Authors:  J Sandoval; J Gaspar; T Pulido; E Bautista; M L Martínez-Guerra; M Zeballos; A Palomar; A Gómez
Journal:  J Am Coll Cardiol       Date:  1998-08       Impact factor: 24.094

View more
  10 in total

Review 1.  Morphological and functional imaging in COPD with CT and MRI: present and future.

Authors:  Julia Ley-Zaporozhan; Sebastian Ley; Hans-Ulrich Kauczor
Journal:  Eur Radiol       Date:  2007-09-27       Impact factor: 5.315

2.  Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension.

Authors:  Henrik ten Freyhaus; Daniel Dumitrescu; Henning Bovenschulte; Erland Erdmann; Stephan Rosenkranz
Journal:  Clin Res Cardiol       Date:  2009-02-13       Impact factor: 5.460

3.  Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).

Authors:  Reiner Frey; Soundos Saleh; Corina Becker; Wolfgang Mück
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

4.  Standard PAH therapy improves long term survival in CTEPH patients.

Authors:  Hans-Juergen Seyfarth; Michael Halank; Heinrike Wilkens; Hans-Joachim Schäfers; Ralf Ewert; Martin Riedel; Ernst Schuster; Hans Pankau; Stefan Hammerschmidt; Hubert Wirtz
Journal:  Clin Res Cardiol       Date:  2010-04-25       Impact factor: 5.460

5.  Endothelin-1 and asymmetric dimethylarginine in children with left-to-right shunt after intracardiac repair.

Authors:  Tsvetomir Loukanov; Raoul Arnold; Jasmin Gross; Christian Sebening; Homa Klimpel; Joachim Eichhorn; Katharina Hoss; Herbert E Ulmer; Matthias Kark; Matthias Gorenflo
Journal:  Clin Res Cardiol       Date:  2008-02-22       Impact factor: 5.460

6.  Absorption of riociguat (BAY 63-2521): bioavailability, food effects, and dose proportionality.

Authors:  Corina Becker; Reiner Frey; Christiane Hesse; Sigrun Unger; Michael Reber; Wolfgang Mück
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

7.  Perioperative sildenafil therapy for pulmonary hypertension in infants undergoing congenital cardiac defect closure.

Authors:  Ashraf A H El Midany; Ezzeldin A Mostafa; Sherif Azab; Ghada A Hassan
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-08-28

8.  Pulmonary hypertension in systemic lupus erythematosus: an independent predictor of patient survival.

Authors:  Hong Ki Min; Jae Ho Lee; Seung Min Jung; Jennifer Lee; Kwi Young Kang; Seung-Ki Kwok; Ji Hyeon Ju; Kyung-Su Park; Sung-Hwan Park
Journal:  Korean J Intern Med       Date:  2015-02-27       Impact factor: 2.884

Review 9.  Macrophage migration inhibitory factor (MIF) in the development and progression of pulmonary arterial hypertension.

Authors:  Mohamed Ahmed; Edmund Miller
Journal:  Glob Cardiol Sci Pract       Date:  2018-06-30

Review 10.  Ramadan fasting: recommendations for patients with cardiovascular disease.

Authors:  Abid Mohammed Akhtar; Nazim Ghouri; C Anwar A Chahal; Riyaz Patel; Fabrizio Ricci; Naveed Sattar; Salman Waqar; Mohammed Yunus Khanji
Journal:  Heart       Date:  2021-05-14       Impact factor: 5.994

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.